Page 3 - Emerald Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) and Skye Bioscience (OTCMKTS:SKYE – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings. Profitability This table compares Nabriva Therapeutics and Skye Bioscience’s […]

Skye Bioscience (OTCMKTS:SKYE – Get Rating) is one of 939 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Skye Bioscience to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk. Analyst Recommendations This is […]

Published: Dec 16, 2020 San Diego, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical biopharmaceutical company focused on developing proprietary molecules with strong clinical and commercial differentiation, announced the publication of a peer-reviewed paper reporting that THCVHS, the Company’s novel THC prodrug, was optimized through a nanoemulsion formulation (THCVHS-NE) for drug delivery into the eye and demonstrated significantly better reduction of intraocular pressure (IOP) compared to the commercia...